Hancock Holding Co. bought a new stake in PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,300 shares of the medical research company’s stock, valued at approximately $906,000.

Other hedge funds also recently bought and sold shares of the company. Envestnet Asset Management Inc. lifted its holdings in shares of PerkinElmer by 28.1% in the first quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 434 shares in the last quarter. Acrospire Investment Management LLC lifted its holdings in PerkinElmer by 185.7% during the second quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,300 shares during the period. Ameritas Investment Partners Inc. bought a new stake in PerkinElmer during the first quarter worth $152,000. LS Investment Advisors LLC lifted its holdings in PerkinElmer by 2.1% during the second quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock worth $196,000 after acquiring an additional 60 shares during the period. Finally, Capital Asset Advisory Services LLC bought a new stake in PerkinElmer during the second quarter worth $222,000. Institutional investors own 91.47% of the company’s stock.

Shares of PerkinElmer, Inc. (NYSE PKI) opened at 68.97 on Friday. The stock has a market capitalization of $7.60 billion, a P/E ratio of 20.80 and a beta of 0.74. PerkinElmer, Inc. has a 52-week low of $45.35 and a 52-week high of $70.16. The firm has a 50-day moving average price of $66.08 and a 200-day moving average price of $63.21.

PerkinElmer (NYSE:PKI) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $547.00 million for the quarter, compared to analysts’ expectations of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. On average, analysts predict that PerkinElmer, Inc. will post $2.89 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.41%. PerkinElmer’s payout ratio is 8.46%.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/30/13300-shares-in-perkinelmer-inc-pki-purchased-by-hancock-holding-co.html.

A number of analysts recently commented on the company. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $67.00 price target on shares of PerkinElmer in a report on Tuesday. Citigroup Inc. reiterated a “buy” rating and set a $80.00 price target (up from $74.00) on shares of PerkinElmer in a report on Tuesday. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 price target on the stock in a report on Tuesday, August 1st. Wells Fargo & Company assumed coverage on PerkinElmer in a report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price target on the stock. Finally, Cowen and Company reiterated a “market perform” rating and set a $70.00 price target (up from $61.00) on shares of PerkinElmer in a report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $67.92.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.